Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
March 6, 2025 / RNAi Obesity Treatment / Arrowhead Pharmaceuticals / Metabolic Disease Therapy / Obesity Clinical Trials
Arrowhead Pharmaceuticals advances two RNAi-based obesity therapeutics, ARO-INHBE and ARO-ALK7, into Phase 1/2 trials. These candidates target adipose and hepatic pathways to enhance fat loss while preserving lean mass, potentially improving metabolic health and obesity management.
Naturally occurring molecule rivals Ozempic in weight loss, sidesteps side effects
March 5, 2025 / BRP Peptide Weight Loss / Ozempic Alternative / Stanford / Metabolic Disease Treatment
Stanford researchers discovered BRP, a naturally occurring peptide that reduces appetite and weight without Ozempic’s side effects. BRP acts via a distinct brain pathway, preserving muscle mass while promoting fat loss. Human trials are planned to evaluate its safety and efficacy.
Egg intake in relation to metabolic health status, serum brain derived neurotrophic factor, and adropin levels in Iranian adults
March 10, 2025 / Metabolic Health / Iran Study / Cardiometabolic Risk Factors / BDNF Adropin Obesity
Higher egg consumption was associated with a lower likelihood of being metabolically unhealthy, particularly in men. However, egg intake showed no significant impact on brain-derived neurotrophic factor (BDNF) or adropin levels. Increased egg intake also correlated with reduced hs-CRP levels and lower blood pressure.
Carbs aren’t the hunger culprit: New research overturns belief that glycemic index drives overeating
March 5, 2025 / Glycemic Index / Carbohydrate-insulin Model / Blood Sugar / Appetite / Metabolic Health
A new study in Cell Metabolism challenges the carbohydrate-insulin model (CIM) by showing that high-glycemic index (GI) foods do not increase hunger or subsequent food intake. While glucose and insulin levels varied, perceived appetite remained unchanged across GI groups.
Motion Sickness Brain Circuit Linked to Obesity in Mice
March 7, 2024 / Motion Sickness / Metabolism / Brain Circuit Obesity Link / Vestibular System / Weight / Obesity Treatment Targets
Researchers identified a brain circuit linking motion sickness to metabolism, showing that inhibiting MVePCGlu neurons increases energy expenditure, reduces weight gain, and improves insulin sensitivity in mice. Findings suggest potential new targets for obesity and motion sickness treatments.
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
March 8, 2025 / Integrase Inhibitors / Weight Gain / HIV Treatment / Metabolic Risks / Cardiometabolic Effects / HIV Drugs / Cardiometabolic Effect / Obesity Risk
Switching to an integrase inhibitor-based HIV regimen increased the risk of obesity, diabetes, hypertension, and metabolic syndrome over five years but did not raise major cardiovascular event (MACE) risk. Long-term monitoring for cardiometabolic complications is recommended.
Hoth Therapeutics Announces Positive Findings on GDNF’s Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
March 4, 2025 / GDNF Obesity Therapy / Hoth Therapeutics / Weight Loss / Insulin Security / Fatty Liver Disease Treatment
Hoth Therapeutics’ preclinical study highlights GDNF’s potential in obesity treatment, showing enhanced fat metabolism, improved insulin sensitivity, and reduced fatty liver disease. Unlike appetite-suppressing drugs, GDNF boosts energy expenditure, offering a novel metabolic approach to weight management.
Malfunctioning Fat Tissue Could Affect How Easily We Lose Weight
March 9, 2025 / Fat Tissue / Obesity / Metabolic Dysfunction / Weight Loss / Subcutaneous Adipose Tissue / Obesity Stigma / Obesity Treatments
Obesity is driven by fat tissue dysfunction, not just lifestyle choices. Research highlights how subcutaneous adipose tissue (SAT) malfunctions, affecting metabolism, inflammation, and insulin resistance. Personalized, biologically targeted treatments are needed to replace outdated, stigma-driven weight-loss approaches.
Memory is impaired in aged rats after 3 days of high-fat eating
March 6, 2025 / High-fat Diet / Memory Loss / Obesity-independent Cognitive Disease / Aging Brain / Metabolism / Neuroinflammation
A high-fat diet impairs memory in aged rats within just three days, triggering brain inflammation independent of obesity. Younger rats showed resilience, likely due to stronger anti-inflammatory responses. Findings highlight diet’s rapid impact on brain aging and cognition.
Diabetes changes the biology of breast cancer, study shows
March 6, 2024 / Diabetes / Breast Cancer / TNBC Brain Metastasis / MicroRNAs Cancer / Obesity-driven Cancer Progression / Metabolic Disorders / Oncology
Diabetes alters triple-negative breast cancer (TNBC) biology, increasing tumor aggressiveness and brain metastasis via fat cell-derived exosomal microRNAs. Findings suggest patients with obesity-driven diabetes may require specialized monitoring and treatment strategies to improve outcomes.
Daily mango consumption may improve insulin sensitivity in overweight or obese adults
March 5, 2025 / Mangos / Insulin Sensitivity / Fruit for Diabetes Prevention / Blood Sugar Control Diet / Insulin Resistance
Daily mango consumption improved insulin sensitivity and pancreatic function in overweight and obese adults without affecting body weight. The study suggests mangos may reduce type 2 diabetes risk, countering concerns about their natural sugar content.
New drug candidate may help combat metabolic dysfunction-associated steatotic liver disease
March 5, 2025 / MASLD Treatment / Senolytic Therapy / Liver Disease / Obesity / Targeting Senescent Cells
A new senolytic drug candidate effectively eliminates senescent liver cells, reducing fat buildup, fibrosis, and liver cancer risk in metabolic dysfunction-associated steatotic liver disease (MASLD). Targeting BCL-xl and BCL-2, it offers a safer, more effective MASLD treatment.
Melatonin protects skeletal muscle from damage caused by “diabesity”
March 5, 2025 / Melatonin / Muscle Health / Diabesity Treatment / Mitochondrial Function Obesity / Skeletal Muscle / Melatonin Metabolic Benefits
Melatonin protects skeletal muscle in diabesity, enhancing mitochondrial function, reducing cellular stress, and preventing muscle deterioration. It promotes a shift to oxidative muscle fibers, mimicking aerobic exercise effects. Findings suggest melatonin as a potential metabolic disease therapy.
Trans-Resveratrol Shows Promise Against Diet-Induced Obesity
March 5, 2025 / Resveratrol / Obesity / Natural Weight Loss Supplements / Oxidative Stress / Insulin Sensitivity
Trans-resveratrol (RSV) improved insulin sensitivity, lipid metabolism, and oxidative stress in rats with diet-induced obesity. It restored key metabolic genes (SIRT1, PGC-1α, GLUT-4) and reduced inflammation and biochemical damage, suggesting potential as a natural obesity treatment.
Efruxifermin reverses MASH-related cirrhosis in Phase 2 trial
March 10, 2025 / Efruxifermin MASH Treatment / Liver Fibrosis Reversal / Liver Disease / MASH Cirrhosis Clinical Trial
Efruxifermin reversed MASH-related compensated cirrhosis in a Phase 2 trial, significantly reducing liver fibrosis and inflammation over 96 weeks. As an FGF21 analog, it addresses metabolic dysfunction in liver disease, showing promise for MASH treatment in ongoing Phase 3 trials.
GLP-1 RAs Cut Cardiovascular Risk in Metabolic Liver Disease
March 6, 2025 / GLP-1 Ras / Liver Disease / MASLD Caardiovascular Risk / GLP-1 Receptor Agonist Benefits / Metabolic Liver Disease Treatment
GLP-1 receptor agonists (GLP-1 RAs) significantly reduced cardiovascular risk, portal hypertension, and mortality in patients with MASLD/MASH over seven years. Findings highlight GLP-1 RAs as a promising treatment for metabolic liver disease beyond diabetes management.
NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology
March 6, 2025 / Icosabutate MASH Treatment / Liver Fibrosis Therapy / AI-assisted Liver Histology / Metabolic Drug / MASH Glycemic Control
Icosabutate significantly improved liver fibrosis in biopsy-confirmed MASH (F1-F3), showing strong anti-fibrotic, anti-inflammatory, and glycemic benefits. AI-assisted and conventional pathology confirmed efficacy, positioning icosabutate as a promising therapy for advanced MASH, potentially in combination with GLP-1 RAs.
Exploring clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine
March 4, 2024 / MASLD Risk Clusters / Precision Medicine Liver Disease / Cardiovascular Risk
MASLD is highly heterogeneous, with distinct risk clusters influencing disease progression, cardiovascular risk, and genetic susceptibility. Identifying MASLD subtypes through data-driven clustering could enable precision medicine approaches, improving risk stratification and targeted treatment strategies.
New Avenues for Treating Metabolic Dysfunction-Associated Fatty Liver Disease
March 10, 2024 / MAFLD Transcription Factor Therapy / FXR Agonists / Liver Disease / PPARs / Metabolic Liver Disease
Targeting transcription factors like FXR, PPARs, and THR-β offers new therapeutic avenues for MAFLD and MASH, addressing lipid metabolism, inflammation, and fibrosis. Emerging drugs, including obeticholic acid and resmetirom, show promise but require further refinement for safety and efficacy.
Coffee Linked With Decreased Risk Of Metabolic Syndrome
March 7, 2024 / Coffee / Metabolic Syndrome / Polyphenols Heart Health / Phenolic Acids / Metabolic Syndrome Prevention / Cardiometabolic Benefits
Higher polyphenol intake, especially from coffee, wine, and chocolate, was linked to a 23% lower risk of metabolic syndrome (MetS). Polyphenols, particularly phenolic acids, improved blood pressure, insulin resistance, and triglyceride levels, supporting cardiometabolic health.